Documents
Glycap-3A (human Fc gamma RIIIA) pre-packed columns are capable of separating non-fucosylated, bisected GlcNAc, IgG1, and IgG3 from complex antibody mixtures of monoclonal or polyclonal IgG. The columns, available in 1 mL and 5 mL sizes, are packed with an affinity resin to which human Fc gamma RIIIA (CD16A) is immobilized.
Glycap-3A is operated by loading a neutral pH and eluting high affinity glycoforms and subclasses at low pH (for example, pH 3-4.5).
Glycap-3A, an affinity resin developed by Zepteon
Glycap-3A is a unique and patented (US10221210B2, EP2734537A1) affinity purification technology, developed by Zepteon, that enables the separation of antibodies based on their glycoform (nonfucyosylated or bisected GlcNAc) and subclass (high affinity for IgG1 and IgG3). The affinity chromatography resin contains optimally immobilized FcgammaR3A receptors, leading to high antibody binding capacities. The FcgammaR3A is glycosylated and represents a superior technology compared to other competitors' non-glycosylated E. coli derived FcgammaR3A ligands, which have limited selectivity.
Bolton et al. Biotechnology Progress, 2013